The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Application of PET in Brain Tumor

뇌종양에서 PET의 임상이용

  • Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • 정준기 (서울대학교 의과대학 핵의학교실)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The annual incidence of primary brain tumors is 7-19 cases per 100,000 people. The unique capacity of visualizing biochemical processes allows PET to determine functional metabolic activities of the brain tumors. Like other malignant tumors, F-18 FDG has been used commonly in the imaging of brain tumors. FDG PET is valuable in grading malignancy, predicting prognosis, monitoring treatment, differentiating tumor recurrence from radiation necrosis, and detecting primary lesion in metastatric brain tumors. Among amino acids labeled with positron emitters, C-11 methionine is used clinically. Tumor delineation is much better with methionine PET than with FDG PET. Low grade gliomas, in particular, are better evaluated with methionine than with FDG. PET opens another dimension in brain tumor imaging. PET imaging has clearly entered the clinical area with a profound impact on patient care in many indications.

Keywords

References

  1. Prados MD, Wilson CB. Neoplasms of the centralnervous system. In: Holland JF, Frei F, Bast RC,Kufe DW, Morton DL, Weichselbaum RR eds.Cancer medicine, vol. 1. Baltimore: Williams andWilkins; 1997. p. 1471-514.
  2. Di Chiro G, Delapaz RL, Brooks RA, Sokoloff L,Kornblith PL, Smith BH et al. Glucose utilizationof cerebral glioma measured by F-18 and PET.Neurology 1982;32:1323-29.
  3. Barker FG, Chang SM, Valk PE, Pounds TR,Prados MD. F-18-fluorodeoxyglucose uptake andsurvival of patients with suspected recurrentmalignant glioma. Cancer 1997;79:115-26.
  4. Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, DiChiro G. Neuroimaging of juvenile pilocyticastrocytomas: An enigma. Radiology 1993;189:221-5.
  5. Holzer T, Herholz K, Jeske J, Heiss WD.FDG-PET as a prognostic indicator inradiochemotherapy of glioblastoma. J Comut AssistTomogr 1993;17:681-7.
  6. De Witte 0, Levivier M, Violon P, Salmon I,Darnhaut P, Wikler D, et al. Prognostic value ofpositron emission tomography with [18F]fluoro-2deoxy-D-glucose in the low-grade glioma.Neurosurgery 1996;39(3):470-7.
  7. Herholz K, Pietrzyk U, Voges J, Schroder R,Halber M, Treuer H, et al. Correlation of glucoseconsumption and tumor cell density in astrocytomas.A stereotactic PET Study. J Neurosurg 1993;79(6):853-8.
  8. De Witte 0, Hildebrand J, Luxen A, Goldman S.Acute effect of carnustine on glucose metabolism inbrain and glioblastoma. Cancer 1994;74:2836-42.
  9. Marriott CJ, Throstad W, Akabani G, Brown MT,McLendon RE, Hanson MW, et al. Locally increased uptake of fluorine-18-fluorodeoxyg1ucoseafter intracavitary administration of iodine-131-labeledantibody for primary brain tumors. J Nucl Med1998;39:1376-80.
  10. Hustinx R, Alavi A. SPECT and PET imaging ofbrain tumors. Neuroimag Clin North Amer1999;9(4):751-66.
  11. Langleben DD and Segall GM. PET indifferentiation of recurrent brain tumor fromradiation injury. J Nucl Med 2000;41:1861-7.
  12. Chung J-K, Kim YK, Kim SK, Lee J, Paek S, YeoS, et al. Usefulness of llC-methionine PET in theevaluation of brain tumors that are hypo- orisometabolism on l8F_FDG PET. Eur J Nucl Med2002;29: 176-82.
  13. Ogawa T, Kanno I, Hatazawa J, Inugami A, FujitaH, Shimosegawa E, et al. Methionine PET forfollow-up of radiation therapy of primary lymphomaof the brain. Radiographies 1994;14:101-10.
  14. Kaschten B, Stevenaert A, Sadzot B, Deperez M,Degueldre C, Fiore GD, et al. Preoperativeevaluation of 54 gliomas by PET withFluorine-18-fluorodeoxyglucose and/or Carbon-llmethionine.J Nucl Med 1998;39(5):778-85.
  15. Goldman S, Levivier M, Pirotte B, Brucher JM,Wikler D, Damhaut P, et al. Regional methionineand glucose uptake in high-grade gliomas: Acomparative study on PET-guided stereotacticbiopsy. J Nucl Med 1997;38:1459-62.
  16. Kubota R, Kubota K, Yamada S, Tada M,Takahashi T, Iwada K, et al. Methionine uptake bytumor tissue: a microautoradiographic comparisonwith FDG. J Nucl Med 1995;36:484-92.
  17. Derlon JM, Chapon F, Noel MH, Khouri S, BenaliK, Petit-Taboue MC, et al. Non-invasive grading ofoligodendrogliomas: correlations between in vivometabolic pattern and histopathology. Eur J NuclMed 2000;27:778-87.
  18. Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E,Valavaara R, Eronen E, et al. Radiotherapytreatment planning and long-term follow-up withelClmethionine PET in patients with low-grade astrocytoma. Int J Radiation Oncology Bio Phys2000;48(1):43-52.
  19. Ogawa T, Kanno I, Shishido F, Inugami A, HigasoS, Fujita H, et al. Clinical value of PET witheSF]-fluorodeoxyglucose and l-methyl-L'Cj-methioninefor the diagnosis of recurrent brain tumor andradiation injury. Acta Radiologica 1991;32:197-202.
  20. Weber WA, Wester HI, Grosu AL, Herz M,Dzewas B, Feldmann HJ, et al. O-(2-C8F]fluoroethyl)L-tyrosine and L-[methyl-11Clmethionine uptake inbrain tumours: initial results of a comparativestudy. Eur J Nucl Med 2000;27(5):542-49.
  21. Hara T, Kosaka N, Shinoura N, Kondo T. PETimaging of brain tumor with [methyl-C-ll]choline.J Nucl Med 1997;38:842-7.